Business Description
InnoCan Pharma Corp
NAICS : 811490
SIC : 5232
ISIN : CA45783P1027
Share Class Description:
HAM:IP40: Ordinary SharesTotal Employee Number:
11Compare
Compare
Traded in other countries / regions
INNO.CanadaIP40.GermanyINNPF.USA IPO Date
2021-01-29Description
InnoCan Pharma Corp develops consumer wellness and pharmaceutical products. It has developed a preclinical-stage Cannabidiol-loaded Liposome injection Platform (CBD-LPT) for non-opioid pain management, and is involved in developing and marketing various self-care and CBD beauty products. Additionally, the Group offers cosmetic products such as anti-aging beauty sleeping masks, anti-puffiness eye serum, anti-aging facial serum, hair cream, etc., which are sold mainly through online marketplaces. Its operating segments are: Online sales and Other operations. The majority of its revenue is generated from the Online sales segment, which engages in the development, manufacture, and marketing of cosmetic products. Geographically, the Group generates maximum revenue from the United States.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 4.68 | |||||
Equity-to-Asset | 0.48 | |||||
Debt-to-Equity | 0.27 | |||||
Debt-to-EBITDA | -2.82 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 0.03 | |||||
WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 108.2 | |||||
3-Year EPS without NRI Growth Rate | 30 | |||||
3-Year Book Growth Rate | -8.8 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 36.89 | |||||
9-Day RSI | 32.97 | |||||
14-Day RSI | 31.87 | |||||
3-1 Month Momentum % | -45.92 | |||||
6-1 Month Momentum % | -52.47 | |||||
12-1 Month Momentum % | -77.03 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 5.52 | |||||
Quick Ratio | 4.4 | |||||
Cash Ratio | 3.4 | |||||
Days Inventory | 354.16 | |||||
Days Payable | 28.99 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -5.4 | |||||
Shareholder Yield % | -12.66 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 89.81 | |||||
Operating Margin % | -10.05 | |||||
Net Margin % | -5.99 | |||||
EBITDA Margin % | -1.99 | |||||
FCF Margin % | -1.51 | |||||
OCF Margin % | -1.47 | |||||
ROE % | -31.86 | |||||
ROA % | -13.8 | |||||
ROIC % | -80.21 | |||||
ROC (Joel Greenblatt) % | -68.83 | |||||
ROCE % | -6.32 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Price-to-Owner-Earnings | 69.46 | |||||
PS Ratio | 0.33 | |||||
PB Ratio | 1.62 | |||||
Price-to-Tangible-Book | 1.61 | |||||
EV-to-EBIT | -10.61 | |||||
EV-to-EBITDA | -11.45 | |||||
EV-to-Revenue | 0.23 | |||||
EV-to-FCF | -14.58 | |||||
Price-to-GF-Value | 0.17 | |||||
| Price-to-Net-Current-Asset-Value | 1.65 | |||||
| Price-to-Net-Cash | 8.58 | |||||
Earnings Yield (Greenblatt) % | -9.43 | |||||
FCF Yield % | -4.69 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
InnoCan Pharma Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 21.738 | ||
| EPS (TTM) (€) | -0.333 | ||
| Beta | -0.7583 | ||
| 3-Year Sharpe Ratio | -0.44 | ||
| 3-Year Sortino Ratio | -0.65 | ||
| Volatility % | 94.06 | ||
| 14-Day RSI | 31.87 | ||
| 14-Day ATR (€) | 0.122423 | ||
| 20-Day SMA (€) | 1.9105 | ||
| 12-1 Month Momentum % | -77.03 | ||
| 52-Week Range (€) | 1.535 - 12.48 | ||
| Shares Outstanding (Mil) | 4.5 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
InnoCan Pharma Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
InnoCan Pharma Corp Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| 0.0153846:1 Stock Split | 2025-09-05 | 7.70 (+0.00%) |
Show
Entries
InnoCan Pharma Corp Frequently Asked Questions
What is InnoCan Pharma Corp(HAM:IP40)'s stock price today?
The current price of HAM:IP40 is €1.63. The 52 week high of HAM:IP40 is €12.48 and 52 week low is €1.54.
When is next earnings date of InnoCan Pharma Corp(HAM:IP40)?
The next earnings date of InnoCan Pharma Corp(HAM:IP40) is .
Does InnoCan Pharma Corp(HAM:IP40) pay dividends? If so, how much?
InnoCan Pharma Corp(HAM:IP40) does not pay dividend.
Press Release
Articles on InnoCan Pharma Corp
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers